Renaissance Capital logo

Samsara Vision Scheduled, Nasdaq: SMSA

Makes medical implants for retinal diseases including AMD.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a specialty medical device company dedicated to bringing vision and freedom back to patients suffering from late-stage conditions of the retina. We are engaged in the research, development, manufacturing, and marketing of proprietary ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders, particularly Age-Related Macular Degeneration (“AMD”). Our current product line consists of: our first-generation implantable miniature telescope (“IMT”), which we refer to as WA IMT; our Smaller-Incision, New Generation (SING) IMT, which we refer to as SING IMT; and our Tsert delivery system. Our WA IMT is the first implantable medical device approved by the U.S. Food and Drug Administration (“FDA”) that works similarly to the telephoto lens of a camera, which enables improvement in vision and quality of life for individuals with the most advanced form of AMD, commonly referred to as late-stage AMD. It is important to note that not every patient with late-stage AMD is a candidate for treatment using our WA IMT. The various, currently held regulatory approvals in different markets carry differing labels that list a number of conditions and contraindications and general exclusion criteria.
more less
IPO News for Samsara Vision
more
IPO Data
IPO File Date 11/03/2021
Offer Price
Price Range $5.00 - $7.00
Offer Shares (mm) 4.2
Deal Size ($mm) $25
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $5.00 - $7.00
Offer Shares (mm) 4.2
Deal Size ($mm) $25
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Far Hills, NJ
Founded 2015
Employees 22
Website www.samsaravision.com